

provide blood samples to measure biochemical measures of dietary intake. The data will be used to assess the magnitude and structure of dietary

measurement error in dietary surveillance and nutritional epidemiologic studies. *Frequency of response:* One-time study. *Affected*

public: Individuals or households. *Types of Respondents:* US adults 40–69 years of age. The annual reporting burden is as follows:

| Data collection | Estimated Number of respondents | Estimated Number of responses per respondent | Average burden hours per response | Estimated total hour burden | Estimated total annual burden hours requested |
|---|---------------------------------|--|-----------------------------------|-----------------------------|---|
| Screener | 400 | 1 | 0.167 | 67 | 67 |
| 24-hour recall #1 | 400 | 1 | 0.5 | 200 | 200 |
| 24-hour recall #2 | 400 | 1 | 0.5 | 200 | 200 |
| Food frequency questionnaire #1 | 400 | 1 | 1 | 400 | 400 |
| Food frequency questionnaire | 400 | 1 | 1 | 400 | 400 |
| Physical activity questionnaire | 400 | 1 | 0.25 | 100 | 100 |
| Opinion forms | 400 | 1 | 0.25 | 100 | 100 |
| Dietary screener questionnaire | 400 | 1 | 0.167 | 67 | 67 |
| Dosing with DLW/initial urine collections | 400 | 1 | 4 | 1600 | 1600 |
| Spot urine collections | 400 | 1 | 0.25 | 100 | 100 |
| 24 hr urine collection #1 | 400 | 1 | 0.167 | 67 | 67 |
| 24 hr urine collection #2 | 400 | 1 | 0.167 | 67 | 67 |
| Blood collection | 400 | 1 | 0.25 | 100 | 100 |
| Total | 400 | 1 | 0.67 | 3,468 | 3,468 |

There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proposed performance of the functions of the agency, including whether the information shall have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimate public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Amy F. Subar, Ph.D., Project Officer, National

Cancer Institute, EPN 313,6130 Executive Blvd MSC 7344, Bethesda MD 20892–7344, or call non-toll-free number (301) 496–8500, or FAX your request to (301) 435–4710, or E-mail your request, including your address, to amy__subar@nih.gov.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: April 15, 1999.

Reesa Nichols,

NCI Project Clearance Liaison.

[FR Doc. 99–10372 Filed 4–23–99; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Sickle Cell Disease Advisory Committee.

Date: June 7, 1999.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: For discussion of program policies and issues.

Place: National Institute of Health, Two Rockledge Center, Suite 9104, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Charles L. Peterson, Director, Blood Diseases Program, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, NIH, Two Rockledge Center, Room 10158, MSC 7950, 6701 Rockledge Drive, Bethesda, MD 20892, 301/435–0050.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research, 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: April 16, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99–10368 Filed 4–23–99; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the